{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:08:29Z","timestamp":1793405309130,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"The Neurofibromatosis unit is funded by the the NHS as a highly specialised service but there is no research funding","award":["There was no specific funding for this study."],"award-info":[{"award-number":["There was no specific funding for this study."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1186\/s12955-017-0607-y","type":"journal-article","created":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T18:33:55Z","timestamp":1487010835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire"],"prefix":"10.1186","volume":"15","author":[{"given":"Rosalie E","family":"Ferner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy D","family":"Leschziner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia K","family":"Afridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F","family":"Golding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,14]]},"reference":[{"key":"607_CR1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S1474-4422(07)70075-3","volume":"6","author":"R Ferner","year":"2007","unstructured":"Ferner R. Neurofibromatosis 1 and Neurofibromatosis 2: a twenty-first century perspective. Lancet Neurol. 2007;6:340\u201351.","journal-title":"Lancet Neurol"},{"key":"607_CR2","doi-asserted-by":"crossref","unstructured":"Ferner RE. Psychological impact of the Neurofibromatoses. In: Ferner RE, Huson SM, Evans DG. London: Neurofibromatoses in clinical practice Springer; 2011. p129-140.","DOI":"10.1007\/978-0-85729-629-0_4"},{"key":"607_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI60578","volume":"23","author":"WJ Jessen","year":"2013","unstructured":"Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013;23:340\u20137. doi: 10.1172\/JCI60578 .","journal-title":"J Clin Invest"},{"key":"607_CR4","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016;375:2550\u201360. doi: 10.1056\/NEJMoa1605943 .","journal-title":"N Engl J Med"},{"key":"607_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/MOP.0000000000000169","volume":"27","author":"MA Karajannis","year":"2015","unstructured":"Karajannis MA, Ferner RE. Neurofibromatosis-related tumours: emerging biology and therapies. Curr Opin Pediatr. 2015;27:26\u201333. doi: 10.1097\/MOP.0000000000000169 .","journal-title":"Curr Opin Pediatr"},{"key":"607_CR6","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s10897-015-9829-5","volume":"24","author":"HA Crawford","year":"2015","unstructured":"Crawford HA, Barton B, Wilson MJ, Berman Y, McKelvey-Martin VJ, Morrison PJ, North KN. The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults. J Genet Couns. 2015;24:931\u201344. doi: 10.1007\/s10897-015-9829-5 .","journal-title":"J Genet Couns"},{"key":"607_CR7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s10897-016-9939-8","volume":"25","author":"NP Bicudo","year":"2016","unstructured":"Bicudo NP, de Menezes Neto BF, da Silva de Av\u00f3 LR, Germano CM, Melo DG. Quality of Life in Adults with Neurofibromatosis 1 in Brazil. J Genet Couns. 2016;25:1063\u201374. doi: 10.1007\/s10897-016-9939-8 .","journal-title":"J Genet Couns"},{"key":"607_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000337548","volume":"224","author":"S Granstrom","year":"2012","unstructured":"Granstrom S, Lanagenbruch A, Augsutin M, Mautner VF. Psychological burden in adult neurofibromatosis type 1 patients: impact of disease visibility on body image. Dermatology. 2012;224:160\u201377. doi: 10.1159\/000337548 .","journal-title":"Dermatology"},{"key":"607_CR9","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/bmj.306.6890.1437","volume":"306","author":"C Jenkinson","year":"1993","unstructured":"Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993;306:1437\u201340.","journal-title":"BMJ"},{"key":"607_CR10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group. EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"607_CR11","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/archderm.137.11.1421","volume":"137","author":"P Wolkenstein","year":"2001","unstructured":"Wolkenstein P, Zeller J, Revuz J, Ecosse E, Lepl\u00e8ge A. Quality-of-Life Impairment in Neurofibromatosis Type 1 A Cross-sectional Study of 128 Cases. Arch Dermatol. 2001;137:1421\u20135.","journal-title":"Arch Dermatol"},{"key":"607_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1477-7525-11-21","volume":"11","author":"K Nutakki","year":"2013","unstructured":"Nutakki K, Hingtgen CM, Monahan P, Varni JW, Swigonski NL. Development of the adult PedsQL\u2122 neurofibromatosis type 1 module: initial feasibility, reliability and validity. Health Qual Life Outcomes. 2013;11:21. doi: 10.1186\/1477-7525-11-21 .","journal-title":"Health Qual Life Outcomes"},{"key":"607_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/s-0032-1301396","volume":"73","author":"RE Hornigold","year":"2012","unstructured":"Hornigold RE, Golding JF, Leschziner G, Obholzer R, Gleeson MJ, Thomas N, Walsh D, Saeed S, Ferner RE. The NIFTI-QOL: a disease specific quality of life questionnaire for neurofibromatosis 2. J Neurol Surg B Skull Base. 2012;73:104\u201311. doi: 10.1055\/s-0032-1301396 .","journal-title":"J Neurol Surg B Skull Base"},{"key":"607_CR14","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00415-014-7303-1","volume":"261","author":"RE Ferner","year":"2014","unstructured":"Ferner RE, Shaw A, Evans DG, McAleer D, Halliday D, Parry A, Raymond FL, Durie-Gair J, Hanemann CO, Hornigold R, Axon P, Golding JF. Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. J Neurol. 2014;261:963\u20139. doi: 10.1007\/s00415-014-7303-1 .","journal-title":"J Neurol"},{"key":"607_CR15","doi-asserted-by":"crossref","unstructured":"National Institutes of Health Consensus Development Conference Statement: Neurofibromatosis. Arch Neurol Chicago. 1988;45:575\u20138","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"607_CR16","first-page":"131","volume":"13","author":"VM Riccardi","year":"1977","unstructured":"Riccardi VM, Kleiner B. Neurofibromatosis: a neoplastic birth defect with two age peaks of severe problems. Birth defects. 1977;13:131\u20138.","journal-title":"Birth defects"},{"key":"607_CR17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/bmj.320.7227.114","volume":"320","author":"C Pope","year":"2000","unstructured":"Pope C, Ziebland S, Mays N. Qualitative research in health care: Analysing qualitative data. BMJ. 2000;320:114\u201316.","journal-title":"BMJ"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-017-0607-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T06:27:37Z","timestamp":1498372057000},"score":1,"resource":{"primary":{"URL":"http:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-017-0607-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1186\/s12955-017-0607-y","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"article-number":"34"}}